Pharmaceutical Research and Manufacturers of America, an industry lobbying group, set aside $150 million in 2009 to support the law â€™s passage. Some lobbyists have tacitly accepted the likelihood that major provisions of the health law will be repealed, setting their sights instead on shaping its replacement. They fear that if they come out strongly in opposition to repealing the law, they will lose their seats at the table as congressional Republicans and the Trump administration negotiate a replacement. 